<DOC>
	<DOCNO>NCT01342367</DOCNO>
	<brief_summary>The purpose study see quality life improve patient receive oral hormone therapy compare standard care . The study also compare survival rate patient receive oral hormone therapy receive standard care .</brief_summary>
	<brief_title>Feasibility Hormones Radiation Intermediate High Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Age &gt; = 70 year and/or Charlson comorbidity index score &gt; = 2 Pathologically ( histologically ) proven diagnosis prostatic adenocarcinoma Two follow intermediate risk feature recurrence , Gleason Score = 7 , PSA 1020 ng/ml , Clinical Stage T2bT2c Percent positive biopsy core &gt; = 50 % One follow high risk feature recurrence , Gleason Score 810 , PSA &gt; 20 ng/ml , Clinical Stage T3aT4 Clinically negative lymph node establish imaging , nodal sampling , dissection No evidence bone metastases bone scan History/physical examination via Charlson Comorbidity Index within 60 day prior registration Zubrod Performance Status 02 Age &gt; = 18 Baseline serum PSA within 60 day prior registration Baseline serum testosterone obtain within 60 day prior registration Study entry PSA serum testosterone must obtain follow time frame , 10day period follow prostate biopsy , follow initiation oral androgen manipulation , within 30 day discontinuation finasteride dutasteride CBC/ differential obtain within 60 day prior registration adequate bone marrow function Patient must able provide studyspecific inform consent prior study entry Liver function parameter follow , Total Bilirubin &lt; = 2 x institutional upper limit normal , AST ( SGOT ) ALT ( SGPT ) &lt; = 2 x institutional upper limit normal Prior radical surgery ( prostatectomy ) , highintensity focus ultrasound ( HIFU ) cryosurgery prostate cancer Prior hormonal therapy , LHRH agonists ( e.g. , goserelin , leuprolide ) , antiandrogens ( e.g. , flutamide , bicalutamide ) , estrogens ( e.g. , DES ) , bilateral orchiectomy Use 5alpha reductase inhibitor ( finasteride , dutasteride ) specifically prescribe treatment prostate cancer Prior concurrent cytotoxic chemotherapy prostate cancer ; prior chemotherapy different cancer permit Prior radiation , include brachytherapy , region prostate would result overlap RT field Active lupus scleroderma Severe , active comorbidity , include limited , unstable angina within last 6 month without subsequent corrective cardiovascular procedure , acute bacterial fungal infection require intravenous antibiotic time registration Hepatic insufficiency AST , ALT , Bilirubin &gt; 2 x upper limit normal , clinical jaundice , and/or coagulation defect Acquired Immune Deficiency Syndrome ( AIDS ) ; note , however , HIV test require entry protocol.Patients HIV seropositive meet criterion diagnosis AIDS eligible study participation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Quality Life</keyword>
</DOC>